Lexicon Pharmaceuticals, Inc. (LXRX): James F Tessmer , VP, Finance & Accounting of Lexicon Pharmaceuticals, Inc. sold 6,000 shares on May 23, 2016. The Insider selling transaction was reported by the company on May 23, 2016 to the Securities and Exchange Commission. The shares were sold at $13.00 per share for a total value of $78,000.00 , the company said in a SEC Form 4 Filing.
Lexicon Pharmaceuticals: On Friday, May 20, 2016 heightened volatility was witnessed in Lexicon Pharmaceuticals which led to swings in the share price. The shares opened for trading at $12.34 and hit $12.525 on the upside , eventually ending the session at $12.44, with a gain of 1.22% or 0.15 points. The heightened volatility saw the trading volume jump to 8,50,690 shares. The 52-week high of the share price is $15.79 and the company has a market cap of $1,291,533 M . The 52-week low of the share price is at $6.91.
Company has been under the radar of several Street Analysts.Lexicon Pharmaceuticals is Reiterated by Wedbush to Outperform and the brokerage firm has raised the Price Target to $ 28 from a previous price target of $26 .The Rating was issued on Mar 2, 2016.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.